Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Enterprise Value (2016 - 2025)

Tandem Diabetes Care's Enterprise Value history spans 13 years, with the latest figure at -$292.7 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 33.23% year-over-year to -$292.7 million; the TTM value through Dec 2025 reached -$292.7 million, up 33.23%, while the annual FY2025 figure was -$292.7 million, 33.23% up from the prior year.
  • Enterprise Value reached -$292.7 million in Q4 2025 per TNDM's latest filing, up from -$319.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$292.7 million in Q4 2025 to a low of -$635.4 million in Q1 2022.
  • Average Enterprise Value over 5 years is -$494.7 million, with a median of -$502.7 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: plummeted 220.48% in 2021, then soared 33.23% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$623.8 million in 2021, then grew by 1.11% to -$616.9 million in 2022, then increased by 24.15% to -$467.9 million in 2023, then grew by 6.32% to -$438.3 million in 2024, then skyrocketed by 33.23% to -$292.7 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Enterprise Value are -$292.7 million (Q4 2025), -$319.1 million (Q3 2025), and -$315.4 million (Q2 2025).